Current Edition

US’s PCI Pharma services to acquire Australian packaging firm

The addition of PPP will mark PCI’s fifth acquisition outside of the U.S. in five years

US firm PCI Pharma Services (PCI) has announced the acquisition of Australia-based Pharmaceutical Packaging Professionals (PPP). Located in Melbourne, Victoria, Australia, PPP is a recognized leader in clinical trial supply with a comprehensive suite of support services including early clinical phase sterile and non-sterile drug manufacture of investigational medicines, packaging and labeling services for investigational products, as well as logistical services including storage and distribution to global investigational sites.
The acquisition of PPP, establishes a presence for PCI in Australia, will help in expansion in the Asia Pacific region. Australia is one of the leading countries for Phase 1 studies globally, and with this acquisition, PPP’s Phase I offering also enables to better support PCI customers from early phases of clinical development through to commercial launch, said PCI in a statement.
The deal will give PCI a strong market presence with Phase I units and entry into  Asia Pacific markets including China, Korea, Vietnam, Sri Lanka, Taiwan, Malaysia, Thailand and New Zealand, and help to grow in the region.
“The addition of PPP is significant for our continued global expansion” stated Bill Mitchell, President and CEO of PCI Pharma Services. “The Asia-Pacific region, including Australia, is a very attractive and growing segment in the clinical trials market. Our customers continue to seek new markets both for execution of their clinical studies as well as partners that can support them through the supply chain.” The addition of PPP will mark PCI’s fifth acquisition outside of the U.S. in five years, which underscores our continued commitment to growth and geographic expansion. “This opportunity is part of our next logical phase of geographic expansion and enables us to support our customers in their long term global growth strategies. Additionally, PPP’s highly experienced management team has a strong track record in the clinical trials marketplace and we are excited to welcome them to PCI.”
PPP’s founder and CEO, Craig Rogers stated “We look forward to joining PCI given its market leading presence and believe PPP’s Phase I offering and Asia Pacific location provides for a powerful combination and strong synergies. I am excited for my new role as Senior Vice President of PCI Asia Pacific and supporting our customers in this expanding region.”